Fast and easy access to PROTACS for your research

Proteolysis targeting chimeras (PROTACs), consisting of two bioactive domains – one E3 ligase binder and one target protein binder –  connected via a linker, can induce selective degradation of proteins and as such, offer a great deal of promise in the drug discovery field. Despite this, one of the major drawbacks is the lead time for PROTAC development, which can involve substantial synthetic and medicinal chemistry.

We have developed a range of methods and cartridges, containing a range of partial PROTACs, which are capable of effecting PROTAC synthesis and purification in an automated manner.

Currently available are the well known VHL and CRBN ligands with linkers of different length. Other ligands, such as the inactive version of these for control experients will be available soon!